SLC5A2 and diabetes mellitus: This study may represent future research directions in the field of AI in cardiology in patients with ischemic heart disease, especially since the authors mention that their paper is the first in the literature to address this topic (the impact of SGLT2 inhibitors on CABG patients with/without chronic kidney disease and with/without type 2 diabetes mellitus who are undergoing a cardiac rehabilitation program) [270].